Who Generates Higher Gross Profit? Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation

Alnylam's 2023 Surge: A Biotech Showdown

__timestampAlnylam Pharmaceuticals, Inc.Bio-Techne Corporation
Wednesday, January 1, 201450561000251411000
Thursday, January 1, 201541097000307277000
Friday, January 1, 201647159000336659000
Sunday, January 1, 201776545000374541000
Monday, January 1, 201873106000432143000
Tuesday, January 1, 2019194688000473491000
Wednesday, January 1, 2020414801000483194000
Friday, January 1, 2021704143000632850000
Saturday, January 1, 2022868601000756496000
Sunday, January 1, 20231517886000769815000
Monday, January 1, 20241924873000769725000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: Alnylam vs. Bio-Techne

In the competitive world of biotechnology, Alnylam Pharmaceuticals and Bio-Techne Corporation have been vying for dominance in gross profit generation. Over the past decade, Bio-Techne consistently outperformed Alnylam until a dramatic shift in 2023. Alnylam's gross profit surged by approximately 75% from 2022 to 2023, reaching a staggering 1.52 billion, surpassing Bio-Techne's 770 million. This remarkable growth highlights Alnylam's strategic advancements and market positioning. Meanwhile, Bio-Techne maintained steady growth, with a 10% increase from 2021 to 2023. The data from 2014 to 2023 reveals a fascinating narrative of growth, competition, and market dynamics. As we look to the future, the absence of data for 2024 leaves us eagerly anticipating the next chapter in this biotech rivalry. Will Alnylam maintain its newfound lead, or will Bio-Techne reclaim its position? Only time will tell.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025